Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

31.58 +0.35 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
From Edgewise Therapeutics
Via Business Wire
News headline image
Speculator’s Watch List: 7 Stocks Ripe for a Short-Squeeze Windfall ↗
Although betting against the bears is risky, the rewards for targeting short-squeeze stocks can also be stratospheric. 
Via InvestorPlace
News headline image
Edgewise Therapeutics: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
News headline image
Where Edgewise Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings for Edgewise Therapeutics ↗
 
Via Benzinga
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. 
Via Benzinga
Topics Stocks
News headline image
Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
News headline image
CIRCOR International, Enovix, Edgewise Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded higher, with the Dow Joned gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
News headline image
Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy ↗
Edgewise Therapeutics Inc (NASDAQ: EWTX) released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with  
Via Benzinga
News headline image
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics ↗
Truist initiated coverage on Edgewise Therapeutics Inc (NASDAQ: EWTX) with a Buy rating and a  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
Top 5 Health Care Stocks That Preparing To Pump This Quarter ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.